RegCell, Inc.
PrivateLast Round
Series A
Sep 15, 2026
Total Funding Raised
$89.8M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
RegCell, Inc. operates in Healthcare & Life Sciences and is based in Emeryville, California. Its latest recorded funding round was a Series A round in September 2026.
RegCell, Inc. is a biotechnology company that develops first-in-class regulatory T-cell (Treg) therapies for autoimmune diseases and transplantation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RegCell, Inc. Comparables
Compare RegCell, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sonoma Biotherapeutics | 87% | |
| GentiBio | 85% | |
| Mozart Therapeutics | 84% |
For institutional investors. Book with your work email.
RegCell, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 15, 2026 | ||||
| Seed | Mar 18, 2025 | ||||
| Grant | Mar 18, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
RegCell, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Seed, Grant |
| Medical Incubator Japan | Series A |
| UTEC (The University of Tokyo Edge Capital Partners) | Series A, Seed |
| Playground Global | Series A |
| Global Brain Corporation | Series A |
| Celadon Partners | Seed |
| LG Technology Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2026
$44M round led by Playground Global.
- Oct 9, 2025
Scientific Founder awarded Nobel Prize in Physiology or Medicine.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 21, 2026
In 2024, RegCell, Inc. receives approximately $37.3 million (¥5.6 billion) in non-dilutive capital from AMED to develop the first generation of its epigenetic reprogramming platform through clinical proof-of-concept in autoimmune liver diseases.
- hiresSep 21, 2026
As part of its financing, RegCell, Inc. plans to add Jory Bell, General Partner at Playground Global, to its Board of Directors on Sep 15th '26.
- receives_financingSep 21, 2026
In Sep '26, RegCell, Inc. receives approximately $22M in non-dilutive funding from AMED, in addition to its Series A, to advance its epigenetic reprogramming platform and expand its clinical pipeline.
For institutional investors. Book with your work email.
RegCell, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RegCell, Inc.'s valuation, stock price, and market status.
Is RegCell, Inc. a public or private company?
RegCell, Inc. is a private company.
What is the current stock price of RegCell, Inc.?
RegCell, Inc. is a private company, so its shares have no public market price. Caplight tracks RegCell, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RegCell, Inc. worth (valuation)?
Valuation information for RegCell, Inc. is not publicly available.
Can I buy RegCell, Inc. stock?
RegCell, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RegCell, Inc.'s last funding round?
RegCell, Inc.'s most recent funding round was Series A on September 15, 2026.
Who are the main investors in RegCell, Inc.?
Key investors in RegCell, Inc. include UTEC (The University of Tokyo Edge Capital Partners), Playground Global, Fast Track Initiative.
Will RegCell, Inc. IPO soon?
No public IPO plans have been announced for RegCell, Inc..
How can I track RegCell, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in RegCell, Inc.'s shares on secondary markets.